Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ELEKTA B

EKTAb.STSE0000163628NASDAQ StockholmSESEK
Stock price
ELEKTA B
Loading chart...

Coverage

Latest articles

Elekta outlines growth strategy, revises order backlog
11 Jun 2025, 19:27EKTAb.STNASDAQ Stockholm

Elekta AB detailed its future growth prospects and the results of a proactive order review at its Investor Update in Stockholm, the company said Tuesday.

Elekta revises order backlog down by 4.9 billion Swedish krona, targets 14% EBIT margin
10 Jun 2025, 09:03EKTAb.STNASDAQ Stockholm

Elekta announced a significant adjustment to its order backlog, cancelling orders valued at 4.9 billion Swedish Krona following a proactive review aimed at improving profitability and predictability.

Elekta names Jakob Just-Bomholt as new President and CEO
9 Jun 2025, 20:29EKTAb.STNASDAQ Stockholm

Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025, the medical technology firm announced.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 20:26EKTAb.STNASDAQ Stockholm

Elekta announced Monday the appointment of Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 17:06EKTAb.STNASDAQ Stockholm

Elekta has named Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025, the company announced.

Elekta reports mixed full-year results amid R&D impairment
8 Jun 2025, 20:30EKTAb.STNASDAQ Stockholm

Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Elekta receives FDA 510(k) clearance for advanced radiotherapy motion management using Elekta Unity MR-Linac28 Feb 2023
Interim report, May-January 2022/2324 Feb 2023
Elekta's climate targets validated by the Science Based Targets initiative (SBTi)24 Feb 2023
First Gamma Knife Esprit patient resumes life as usual only days after brain surgery15 Feb 2023
Elekta to strengthen market position in Asia through acquisition of Thai distributor13 Feb 2023
Elekta Foundation's cancer care successes in Rwanda to be expanded in other low-income countries6 Feb 2023
Invitation to the presentation of Elekta's third quarter 2022/2331 Jan 2023
First ever patient treated for pancreatic cancer with new advanced radiotherapy motion management using Elekta Unity MR-Linac12 Dec 2022
Interim report, May-October 2022/2324 Nov 2022
Swedish and Jordanian royalty inaugurate Elekta radiation therapy devices for cancer and brain disease17 Nov 2022
Invitation to the presentation of Elekta's second quarter 2022/237 Nov 2022
Elekta's Nomination Committee for the 2023 Annual General Meeting31 Oct 2022
  • Previous
  • 1
  • More pages
  • 7
Search
Company
ELEKTA B
EKTAb.STNASDAQ Stockholm
Website: Unavailable
Coverage
12
  • Next
  • 8
  • 9
  • More pages
  • 59
  • Next
  • Filings
    703